Hanna Bandos, Pedro A Torres-Saavedra, Eva Culakova, Heather J Gunn, Minji K Lee, Fenghai Duan, Reena S Cecchini, Joseph M Unger, Amylou C Dueck, Jon A Steingrimsson
{"title":"Best practices and pragmatic approaches for patient-reported outcomes and quality of life measures in cancer clinical trials.","authors":"Hanna Bandos, Pedro A Torres-Saavedra, Eva Culakova, Heather J Gunn, Minji K Lee, Fenghai Duan, Reena S Cecchini, Joseph M Unger, Amylou C Dueck, Jon A Steingrimsson","doi":"10.1093/jncimonographs/lgae047","DOIUrl":null,"url":null,"abstract":"<p><p>Patient-reported outcomes (PROs) are often collected in cancer clinical trials. Data obtained from trials with PROs are essential in evaluating participant experiences relating to symptoms, financial toxicity, or health-related quality of life. Although most features of clinical trial design, implementation, and analyses apply to trials with PROs, several considerations are unique. In this paper, we focus on specific issues such as selection of the tool, timing and frequency of assessments, and data collection methods. We discuss how the estimand framework can be used in connection with PROs, properties of common estimation methods, and handling of missing outcomes. With a plethora of literature available, we aim to summarize best practices and pragmatic approaches to the design and analysis of the studies incorporating PROs.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":"2025 68","pages":"14-21"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848031/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgae047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Patient-reported outcomes (PROs) are often collected in cancer clinical trials. Data obtained from trials with PROs are essential in evaluating participant experiences relating to symptoms, financial toxicity, or health-related quality of life. Although most features of clinical trial design, implementation, and analyses apply to trials with PROs, several considerations are unique. In this paper, we focus on specific issues such as selection of the tool, timing and frequency of assessments, and data collection methods. We discuss how the estimand framework can be used in connection with PROs, properties of common estimation methods, and handling of missing outcomes. With a plethora of literature available, we aim to summarize best practices and pragmatic approaches to the design and analysis of the studies incorporating PROs.